NuCana to Participate in the 7th Annual Truist Securities Life Sciences Summit
NuCana plc (NASDAQ: NCNA) announced that CEO Hugh Griffith and CFO Don Munoz will participate in one-on-one meetings at the 7th Annual Truist Securities Life Sciences Summit on May 4-5, 2021. NuCana focuses on advancing cancer treatment through its ProTide technology, aiming to improve efficacy and safety of chemotherapy agents. Its pipeline includes three ProTides: Acelarin, in Phase III for advanced biliary tract and pancreatic cancer; NUC-3373, in Phase I/IB for various advanced solid tumors; and NUC-7738, in Phase I for advanced solid tumors.
- None.
- None.
EDINBURGH, United Kingdom, April 28, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at the 7th Annual Truist Securities Life Sciences Summit being held virtually from May 4 to May 5, 2021.
Event: 7th Annual Truist Securities Life Sciences Summit
Date: May 4 to May 5, 2021
About NuCana
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is in a Phase III study for patients with advanced biliary tract cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3’-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.
Forward-Looking Statements
This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company’s goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission (“SEC”) on March 4, 2021, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.
For more information, please contact:
Hugh S. Griffith
Chief Executive Officer
NuCana plc
Tel: +44 131 357 1111
info@nucana.com
Westwicke, an ICR Company
Chris Brinzey
Tel: +1 339-970-2843
chris.brinzey@westwicke.com
RooneyPartners
Marion Janic
Tel: +1 212-223-4017
mjanic@rooneyco.com
FAQ
What is the date of the 7th Annual Truist Securities Life Sciences Summit for NCNA?
Who will represent NCNA at the Truist Securities Life Sciences Summit?
What technologies does NCNA use to improve cancer treatments?
What clinical stages are NCNA's ProTides currently in?
What is the focus of NCNA's drug development?
